HLB Therapeutics Co.,Ltd.
115450
Peringkat dalam Saham
#18702
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Harga Saham
$2.01
Kapitalisasi Pasar
$189.24M
Perubahan (1 hari)
7.15%
Perubahan (1 tahun)
-1.89%
Negara
KR
Perdagangan HLB Therapeutics Co.,Ltd. (115450)
Kategori
Healthcare
Rasio P/S untuk HLB Therapeutics Co.,Ltd. (115450)
Rasio P/S per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari HLB Therapeutics Co.,Ltd., rasio P/S saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/S perusahaan adalah 0.
Riwayat rasio P/S untuk HLB Therapeutics Co.,Ltd. dari 2026 hingga 2026
Rasio P/S pada akhir setiap tahun
| Tahun | Rasio P/S | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Rasio P/S untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/S | Perbedaan Rasio P/S | Negara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
